Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM - 5 - TR

Cheryl M. Corcoran; Vijay A. Mittal; Scott W. Woods

doi:10.1001/jamapsychiatry.2021.0838

Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM - 5 - TR

Cheryl M. Corcoran^*, Vijay A. Mittal, Scott W. Woods

^*Corresponding author for this work

Psychology

Research output: Contribution to journal › Comment/debate › peer-review

1 Scopus citations

Original language	English (US)
Pages (from-to)	821-822
Number of pages	2
Journal	JAMA Psychiatry
Volume	78
Issue number	8
DOIs	https://doi.org/10.1001/jamapsychiatry.2021.0838
State	Published - Aug 2021

ASJC Scopus subject areas

Psychiatry and Mental health

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1001/jamapsychiatry.2021.0838

Cite this

@article{4caaae4f2a1a4a4eadf3291fbc6fef52,

title = "Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM - 5 - TR",

author = "Corcoran, {Cheryl M.} and Mittal, {Vijay A.} and Woods, {Scott W.}",

note = "Funding Information: received grants from the National Institutes of Health, Substance Abuse and Mental Health Services Administration, and Boehringer Ingelheim; personal fees from Boehringer Ingelheim, New England Research Institute, and Takeda; and has a patent issued for a method of treating prodromal schizophrenia with glycine agonists. No other disclosures were reported.",

year = "2021",

month = aug,

doi = "10.1001/jamapsychiatry.2021.0838",

language = "English (US)",

volume = "78",

pages = "821--822",

journal = "JAMA Psychiatry",

issn = "2168-622X",

publisher = "American Medical Association",

number = "8",

}

TY - JOUR

T1 - Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM - 5 - TR

AU - Corcoran, Cheryl M.

AU - Mittal, Vijay A.

AU - Woods, Scott W.

N1 - Funding Information: received grants from the National Institutes of Health, Substance Abuse and Mental Health Services Administration, and Boehringer Ingelheim; personal fees from Boehringer Ingelheim, New England Research Institute, and Takeda; and has a patent issued for a method of treating prodromal schizophrenia with glycine agonists. No other disclosures were reported.

PY - 2021/8

Y1 - 2021/8

UR - http://www.scopus.com/inward/record.url?scp=85106163672&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85106163672&partnerID=8YFLogxK

U2 - 10.1001/jamapsychiatry.2021.0838

DO - 10.1001/jamapsychiatry.2021.0838

M3 - Comment/debate

C2 - 33978689

AN - SCOPUS:85106163672

VL - 78

SP - 821

EP - 822

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 8

ER -

Attenuated Psychosis Syndrome Should Be Moved to the Main Section in DSM - 5 - TR

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Cite this